Some of our recent news articles.
ProteoNic, a provider of technology and services for efficient production of biologics, has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences. Gilead gains non-exclusive commercial rights for application of ProteoNic's technology platform to the development of its proprietary products from mammalian cells. Financial details of the agreement were not disclosed.
ProteoNic's protein expression technology improves production levels across a range of mammalian host cells and selection systems. It is applicable to all relevant protein classes, including standard antibodies, bispecifics, recombinant polyclonals and complex multi-chain molecules, and enables the economically viable production of difficult to express proteins.